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A b s t r a c t
Background: The practice guidelines of cardiological and diabetological societies emphasise that cardiovascular (CV) risk
control in diabetic patients is especially important and should be stricter than in subjects without diabetes. There are little
data on the frequency of meeting treatment goals in patients with newly diagnosed diabetes mellitus type 2 (DM2).
Aim: To characterise Polish patients with DM2 diagnosed within the previous two years and to assess if the treatment targets
from the current (2008) guidelines of Diabetes Poland regarding control of CV risk factors are met.
Methods: ARETAEUS1 was a cross-sectional questionnaire-based study conducted in various regions of Poland in 2009
(January–April). It involved 1,714 patients of all ages and both genders, who had DM2 treated for less than 24 months. They
were recruited by randomly selected physicians.
Results: Total cholesterol treatment goal (< 4.5 mmol/L) was met in 22% of all patients, triglycerides treatment goal (< 1.7 mmol/L)
in 44%, LDL cholesterol treatment goal (< 2.6 mmol/L) in 20% and HDL cholesterol treatment goal (> 1.0 mmol/L
in men and > 1.3 mmol/L in women) in 55%. Only 13% of the overall population met the goal of blood pressure (BP) below
130/80 mm Hg. When a less restrictive BP control threshold (< 140/90 mm Hg) was applied, 48% of patients had their BP
below the threshold. In the analysis of subgroups (patients with and without previous CV events; receiving 1–5 or not receiv-
ing antihypertensive drugs; receiving and not receiving statins and fibrates) we observed  from 0% to 3.3% of patients meeting
three (HbA1c, BP and cholesterol) treatment goals. The percentages of patients meeting two out of three treatment goals
were between 8% and 33% in different subgroups. The percentages of patients meeting only one out of three treatment goals
ranged from 27.8% to 46.7% or at least one — from 39% to 69%.
Conclusions: Most patients with newly diagnosed diabetes are not meeting their treatment goals regarding control of CV risk
factors, which indicates relatively low adherence to national guideline recommendations for diabetes control and primary CV
prevention in DM2. Difficulties in achieving CV treatment targets in the diabetic population indicate the need for a great deal
of effort on the part of clinicians and patients. Practice guidelines developers should consider what treatment targets are
achievable at a reasonable expense of effort.
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INTRODUCTION
Type 2 diabetes (DM2) increases the cardiovascular (CV) risk
[1]. Patients with diabetes have twice the risk of incident myo-
cardial infarction (MI) and stroke as that of the general po-
pulation. Large numbers of them do not survive their first
event. As many as 80% of patients with DM2 will develop,
and possibly die of, macrovascular disease. This is associated
with a great societal cost, with major loss of life expectancy
and quality of life [2, 3].
That is why the practice guidelines of cardiological and
diabetological societies emphasise that CV risk factors con-
trol in diabetes is especially important and should be stricter
than in people without diabetes (targets for blood pressure
[BP] and lipids are more restrictive) [4–9]. There are little data
on meeting treatment goals in patients with newly diagnosed
DM2. The aim of the ARETAEUS1 study was to identify the
Polish population in whom DM2 had been diagnosed within
the previous two years, to assess if the treatment targets from
the current (2008) guidelines of Diabetes Poland (DP) are
being met to a satisfactory extent, and if the implementation
of preventive strategies is adequate. We present results con-
cerning the control of CV risk factors in this population. The
DM2 is one of the priorities of CV disease prevention in clini-
cal practice [6].
METHODS
The details of the ARETAEUS1 study design, protocol and
patient characteristics have been described elsewhere [10].
In brief, ARETAEUS1 was a cross-sectional questionnaire-
-based study conducted in various regions of Poland between
January and April 2009. The study aimed to identify the cha-
racteristics of patients with newly diagnosed DM2 (defined as
diabetes diagnosed within the previous two years according
to the current criteria outlined in DP clinical practice guideli-
nes 2008, which are consistent with those of the American
Diabetes Association [11]) and to assess if and how many tre-
atment goals recommended by the DP clinical practice gu-
idelines 2008 were being met [4].
The inclusion criteria for the study were: adult patients
of either gender and any age, who had a diagnosis of DM2
within the previous two years (i.e. after 1 January, 2007).
A random sample of clinicians stratified according to the size
of the place of residence (five categories) was drawn from
a database containing data of about 85% of all physicians re-
gistered in Poland. The patients were recruited over one
month and each physician was asked to recruit at least five
patients who fulfilled the inclusion criteria; 333 clinicians who
agreed to participate and returned questionnaires (227 non-
-diabetologists, mainly working in primary health care insti-
tutions and 106 specialists in diabetology [specialists or phy-
sicians who completed their training in diabetology, and who
worked in diabetes outpatient clinics]) recruited 1,714 pa-
tients. The study questionnaires were filled in by physicians;
no data were obtained directly from the patients.
The questionnaire contained items regarding patient cha-
racteristics and medical history (demographic data, CV medi-
cal history [CV events, hypertension and lipid disorders ac-
cording to the report of a participating physician based on
the current criteria outlined in clinical practice guidelines],
medical history concerning diabetes [11], tests results [BP,
glycosylated haemoglobin — HbA1c and lipid levels] as well
as diabetic drugs [11], antihypertensive drugs, lipid lowering
and antiplatelet drugs) and did not include any personal data.
Statistical analysis
Results are presented as mean ± SD or numbers and percenta-
ges. We compared proportions of patients achieving treatment
goals in different subgroups with c2 test. For the comparison of
the means the t-test was used (for normal distribution), and the
Mann-Whitney U test and Kruskal-Wallis test (for non-normal
distribution of the variable). Distribution was estimated on the
basis of skewness coefficient and graphical picture. The t-test for
equal or nonequal variances was used depending on the result
of Levene’s test. A p value < 0.05 was considered significant.
All statistical analyses were conducted using SPSS v. 14.0.
RESULTS
Results related to diabetes control have been described else-
where [12]. Seventy one per cent of all patients had HbA1c
level above or equal to 6.5%. The current article describes
the CV aspects of treatment and care of diabetic patients par-
ticipating in the ARETAEUS1 study.
Mean age of patients was 60 ± 11 years, 50% were fe-
male, mean body mass index (BMI) was 30.6 ± 4.9 kg/m2,
52% had BMI > 30 kg/m2. Mean time from diabetes diagno-
sis was 9.8 ± 7.6 months, 64% were diagnosed with diabetes
for less than a year. Mean waist circumference was 96.4 ±
± 13.4 cm in females and 103.1 ± 12.7 cm in males.
Eighty three per cent of patients fulfilled the Internatio-
nal Diabetes Federation criteria for the diagnosis of metabo-
lic syndrome [13]. Cardiovascular disease risk factors were
common: 77% of patients were reported to have hyperten-
sion, 73% — lipid disorders and 10.5% — previous acute
coronary syndromes.
Total cholesterol treatment goal (< 4.5 mmol/L) was met
in 22% of all patients, triglycerides treatment goal (< 1.7 mmol/L)
in 44%, LDL cholesterol treatment goal (< 2.6 mmol/L) in
20% and HDL cholesterol treatment goal (> 1.0 mmol/L in
men and > 1.3 mmol/L in women) in 55%. There were signi-
ficant differences in the numbers of patients achieving these
targets between patients using and not using statins, using
and not using fibrates and in patients with the diagnosis of
lipid disorders (or taking hypolipidaemic drugs) and without
such a diagnosis (or not taking drugs) (Table 1). In each case,
use of medications indicated generally worse status of risk
factor control.
Eighty three per cent of patients with coronary heart dise-
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Table 1. Lipid level control and lipid lowering drugs
Variable Overall Patients Patients Patients with Patients without
 population, % using statins using fibrates the diagnosis of lipid the diagnosis of lipid
(n = 1,684) Yes No Yes No disorders or taking disorders and not
(n = 1,041) (n = 673) (n = 227) (n = 1,487) drugs (n = 1,331) taking drugs (n = 353)
Total cholesterol: (n = 1,580) (n = 1,293) (n = 272)
< 4.5 mmol/L 22.0 (348) 20.3 (206) 25.2 (142)* 15.3 (34) 23.1 (314)* 18.9 (244) 36.0 (98)^
≥ 4.5 mmol/L 78.0 (1,232) 79.7 (811) 74.8 (421) 84.7 (188) 76.9 (1,044) 81.1 (1,049) 64.0 (174)
LDL cholesterol: (n = 1,220) (n = 1,008) (n = 202)
< 2.6 mmol/L or if CHD < 1.8 mmol/L 19.9 (243) 15.3 (124) 29.1 (119)* 18.4 (29) 20.2 (214) 16.2 (163) 39.1 (79)^
≥ 2.6 mmol/L or if CHD ≥ 1.8 mmol/L 80.1 (976) 84.7 (687) 70.9 (290) 81.6 (129) 79.8 (848) 83.8 (845) 60.9 (123)^
HDL cholesterol: (n = 1,322) (n = 1,096) (n = 214)
> 1.0 mmol/L males, > 1.3 mmol/L females 55.3 (731) 54.0 (471) 57.9 (260) 46.8 (88) 56.7 (643)* 53.2 (583) 65.0 (139)^
< 1.0 mmol/L males, < 1.3 mmol/L females 44.7 (591) 46.0 (402) 42.1 (189) 53.2 (100) 43.3 (491) 46.8 (513) 35.0 (75)
Triglycerides: (n = 1,489) (n = 1,226) (n = 251)
< 1.7 mmol/L 44.3 (660) 40.2 (391) 52.0 (269)* 16.1 (35) 49.2 (625)* 37.1 (455) 78.5 (197)^
≥ 1.7 mmol/L 55.7 (829) 59.8 (581) 48.0 (248) 83.9 (183) 50.8 (646) 62.9 (771) 21.5 (54)
*Significant difference between patients taking and not taking drug (statin, fibrate); ^significant difference between patients with and without lipid disorders; CHD — coronary heart disease; LDL — low density
lipoprotein; HDL — high density lipoprotein. Numbers in brackets — number of valid questionnaires
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all three goals, 12.5% met two goals, 35.3% met only one
goal, and 50.7% met none of the treatment goals (Fig. 5, Ta-
ble 5). In different subgroups, from 0% to 3.3% of patients
met all three treatment goals. More patients without previous
CV events met three, two or one treatment goals as compa-
red with patients with previous CV events. In most subgro-
ups, the percentage of patients not meeting any of the treat-
ment goals varied between 31% and 61%. The percentages
of patients meeting two out of three treatment goals were
between 8% and 33% in different subgroups. The percentage
of patients meeting only one out of three treatment goals ran-
ged from about 27.8% to 46.7% and at least one of the treat-
ment goals — from 39% to 69%.
DISCUSSION
This is the first Polish study which provides information on
CV risk factors profile and lipid-lowering, antihypertensive and
antiplatelet treatment in patients with newly diagnosed (i.e.
within two years of diagnosis) DM2. To date, the studies ad-
dressing similar problems have been conducted in the gene-
ral population, in patients with CV disease and in patients
with DM1 or DM2 lasting 4–10 years.
Achieving all of the treatment goals (HbA1c, BP and lipid
values) was very uncommon in this population (1.4% of pa-
tients), and the proportion achieving some of these goals was
also unsatisfactory.
The results clearly indicate either inadequate adherence
to national clinical practice guideline recommendations, or
that those guidelines are too rigorous in their treatment goals.
The fact that the BP treatment goal (< 130/90) was fulfilled in
13% of patients, while a less restrictive goal (140/90) was ful-
filled in 48% makes the second possibility more probable.
The percentage of patients reaching treatment goals is similar
to that observed in other European studies [14, 15], which
also supports the hypothesis that the treatment goals are rela-
Table 3. Use of acetylsalicylic acid, statins and antihypertensive
drugs according to age
Age groups Total (n = 1,714)
< 40 years (n = 72) 11.1 (8)
41–50 years (n = 229) 27.9 (64)
51–60 years (n = 627) 37.6 (236)
61–70 years (n = 467) 48.8 (228)
> 70 years (n = 305) 52.1 (159)
Figure 1. Statin use (%) in subgroups of patients with newly diagnosed diabetes participating in the ARETAEUS1 study; abbrevia-
tions as in Table 1
Figure 2. Coronary heart disease (CHD), hypertension (diagnosis
or using antihypertensive drugs) and lipid disorders (diagnosis
or using lipid lowering drugs) in patients with newly diagnosed
diabetes participating in the ARETAEUS1 study by age group.
For all diseases, significant differences across all age categories
p < 0.05
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tively too strict and not easily enough reached in clinical prac-
tice. In some guidelines this problem has also been noticed.
The most recent position statement of the European Society
of Hypertension [16, 17] contains a less strong recommenda-
tion to achieve BP below 130/80 mm Hg in diabetic patients
than those featured in the previous guidelines of this society
[18]. Moreover, in one study [19], tight control of systolic BP
(< 130 mm Hg) in patients with diabetes and CHD was not
associated with improved CV outcomes compared to usual
control (systolic BP < 140 mm Hg).
The new DP guidelines (2011) also recommend less strin-
gent target BP of < 140/90 mm Hg in all diabetic patients except
those with newly diagnosed hypertension and those with
diabetic nephropathy (who should aim at < 130/80 mm Hg
values) [20].
We cannot exclude the possibility that physicians do not
put enough attention into prevention and do not find time to
explain to patients the importance of prevention, and that
results in low compliance of patients (especially with newly
diagnosed DM2).
Another possibility is illustrated by the fact that in an
observational study (POLKARD Study Group) over 60% of
subjects without the diagnosis of hyperlipidaemia and not
receiving hypolipaemic drugs had total cholesterol and
LDL-cholesterol levels above the treatment goals [21]. It shows
that risk factors are not only managed inadequately but are
also under-diagnosed.
Hypertension was better diagnosed in our population of
patients. Only 15% of patients without the diagnosis of
Figure 4. The number of antihypertensive drugs used in patients
with newly diagnosed diabetes participating in the ARETAEUS1
study. There was significant difference between patients with
and without hypertension (HN) in all categories together (patients
without HN had zero drugs use, or in one case use of one drug)
Figure 3. Blood pressure (BP) control and diagnosis of hypertension in patients with newly diagnosed diabetes participating in the
ARETAEUS1 study; A. More rigorous BP therapeutic goal. There were significant differences between patients with and without





hypertension and not taking antihypertensive drugs had
BP > 140/90 mm Hg.
In our study, in the subgroup of patients with diagnosed
hypertension, only 2% of those with BP above 130/80 mm Hg
did not receive any antihypertensive drug. So the problem is
not with deciding on initiation of the pharmacological treat-
ment for patients with diagnosed hypertension, but rather with
inadequate drug use — too often only one drug is used, and
we can also assume that the doses are too low. In a study
assessing the competence of Polish general practitioners in
terms of their compliance with hypertension treatment gu-
idelines, poor compliance with guidelines was noted for pa-
tients with diabetes mellitus [22].
The adherence to clinical practice guidelines is better when
the recommendations are clear, simple and easy to follow (e.g.
using specific drugs in specific clinical situations — ASA in CHD
[83% of study participants with CHD received it] or beta-bloc-
Table 4. Classes of antihypertensive drugs used in studied patients
Drug classes Overall Patients with diagnosis Patients without diagnosis
population of hypertension or taking of hypertension and not
(n = 1,689) antihypertensive taking antihypertensive
drugs (n = 1,384) drugs (n = 305)
ACEI 64.9 (1,112) 74 (108) 79.9 (989) 0* 0*
ARB 13.3 (228) 13.7 (20) 16.6 (206) 0* 0*
Diuretic 38.7 (664) 45.2 (66) 47.8 (592) 0* 0*
Calcium blocker 24.2 (415) 28.1 (41) 29.5 (365) 0* 0*
Beta-blocker in patients 32.7 (543) 46.5 (66) 39.5 (470) 0* 0*
without MI (n = 1,661)
*Significant difference between patients with and without hypertension; ACEI — angiotensin converting enzyme inhibitor; ARB — angiotensin receptor
blocker; MI — myocardial infarction
ker in patients with previous MI [85% of this population rece-
ived this drug]). Similar proportions were observed in the Po-
lish parts of the EUROASPIRE (European Action on Secondary
Prevention through Intervention to Reduce Events) III survey
conducted among hospitalised patients with CHD [23].
The results of the ARETAEUS1 study provide valuable
information for doctors and nurses delivering care to patients
with diabetes and those teaching medical students, but also
for experts developing practice guidelines. The information
is directed mostly to a Polish audience, but issues are likely
to be general. Clinicians can find out how their colleagues
manage newly diagnosed diabetes. Clinicians who teach stu-
dents and diabetic patients should, on the basis of these
results, point out to their audiences that as CV prevention is
important in diabetes, there are major difficulties in achie-
ving treatment targets, so much effort is required on the part
of clinicians and patients. Authors of practice guidelines sho-
Figure 5. Meeting treatment goals in patients with newly diagnosed diabetes participating in the ARETAEUS1 study — results in
subgroups according to current lipid lowering treatment (n = 623) and previous cardiovascular (CV) events (n = 609). There was
significant difference between groups in each category (i.e. with and without previous CV events etc.)
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uld pay attention to what is achievable at a reasonable expen-
se of effort and should consider direct proven benefits and
costs (money, time and effort) required to achieve treatment
targets.
CONCLUSIONS
1. Most patients with newly diagnosed diabetes are not me-
eting their treatment goals regarding control of CV risk
factors, which indicates relatively low adherence to na-
tional guideline recommendations for diabetes control
and primary CV prevention in DM2.
2. Clinicians who teach students and diabetic patients sho-
uld point out that there are difficulties in achieving treat-
ment targets in the diabetic population, meaning that
a great deal of effort is required on the part of clinicians
and patients to meet these goals.
3. Practice guidelines developers should consider which tre-
atment targets are achievable at a reasonable expense of
effort.
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Kontrola czynników ryzyka sercowo−
−naczyniowego u polskich chorych
na cukrzycę typu 2 dwa lata od rozpoznania
choroby: wyniki badania ARETAEUS1
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S t r e s z c z e n i e
Wstęp: W wytycznych praktyki klinicznej opracowywanych przez kardiologiczne i diabetologiczne towarzystwa naukowe
podkreśla się, że kontrola sercowo-naczyniowych czynników ryzyka jest szczególnie ważna u chorych na cukrzycę i powinna
być ściślejsza niż u osób bez cukrzycy. Nie ma wielu danych na temat częstości spełniania kryteriów kontroli choroby u osób
ze świeżo rozpoznaną cukrzycą typu 2.
Cel: Celem pracy było scharakteryzowanie chorych na cukrzycę typu 2 rozpoznaną w ciągu ostatnich 2 lat w Polsce i ocena
spełnienia kryteriów kontroli cukrzycy dotyczących czynników ryzyka sercowo-naczyniowego zalecanych w wytycznych
praktyki klinicznej Polskiego Towarzystwa Diabetologicznego z 2008 r.
Metody: ARETAEUS1 było przekrojowym badaniem kwestionariuszowym przeprowadzonym w wielu regionach Polski
w 2009 r. (styczeń–kwiecień). Badaniem objęto 1714 chorych na cukrzycę typu 2 w każdym wieku i obu płci leczonych
przez < 24 miesiące, włączonych do badania przez losowo wybranych lekarzy.
Wyniki: Kryterium wyrównania stężenia: cholesterolu całkowitego (< 4,5 mmol/l) spełniło 22% chorych, triglicerydów
(< 1,7 mmol/l) — 44%, cholesterolu LDL (< 2,6 mmol/l) — 20%, a cholesterolu HDL (> 1,0 mmol/l u mężczyzn i > 1,3 mmol/l
u kobiet) — 55% osób. Jedynie 13% pacjentów spełniło kryterium wyrównania ciśnienia tętniczego < 130/80 mm Hg. Gdy
zastosowano mniej restrykcyjne kryterium wyrównania ciśnienia tętniczego (< 140/90 mm Hg) u 48% osób stwierdzono
ciśnienie tętnicze poniżej tego progu. W analizie przeprowadzonej w podgrupach (osób bez i po przebytych incydentach
sercowo-naczyniowych; otrzymujących 1–5 lub nieotrzymujących leków przeciwnadciśnieniowych, otrzymujących i nie-
otrzymujących statyn i fibratów) zaobserwowano, że 0–3,3% chorych spełniło 3 kryteria kontroli choroby (HbA1c, ciśnienie
tętnicze i stężenie cholesterolu). Odsetki pacjentów spełniających 2 z 3 kryteriów kontroli choroby wynosiły w różnych
podgrupach 8–33%. Odsetki chorych spełniających 1 z 3 kryteriów kontroli choroby wynosiły 27,8–46,7%, a spełniających
co najmniej 1 kryterium kontroli choroby — 39–69%.
Wnioski: Większość osób ze świeżo rozpoznaną cukrzycą typu 2 nie spełniło kryteriów kontroli cukrzycy dotyczących czyn-
ników ryzyka sercowo-naczyniowego, co wskazuje na stosunkowo małą częstość przestrzegania polskich zaleceń klinicznych
dotyczących kontroli cukrzycy i pierwotnej profilaktyki sercowo-naczyniowej w cukrzycy typu 2. Trudności w osiągnięciu
sercowo-naczyniowych celów leczenia u chorych na cukrzycę wskazują na potrzebę podjęcia wysiłków ze strony lekarzy
i pacjentów skierowanych na osiągnięcie tych celów. Osoby opracowujące wytyczne praktyki klinicznej powinny rozważyć,
jakie kryteria kontroli czynników ryzyka są możliwe do osiągnięcia przy racjonalnym nakładzie wysiłków.
Słowa kluczowe: badanie przekrojowe, choroba sercowo-naczyniowa, cukrzyca typu 2, wytyczne praktyki klinicznej
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